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Abstract
Background: Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal neoplasms of
uncertain malignant potential, which have in common the co-expression of muscle and melanocytic
immunohistochemical markers.
Case presentation: A 48-year-old man presented with dysuria, passage of urinary sediment and
lower abdominal discomfort. A three centimeter mass was identified by cystoscopy in the posterior
midline of the bladder. Computerized tomography suggested an enterovesical fistula. The patient
underwent laparotomy, partial cystectomy and partial small bowel resection. Pathological
examination revealed PEComa of the bladder. The patient underwent adjuvant interferon-α
immunotherapy. Subsequent follow-up procedures, including cystoscopy and imaging, have not
revealed evidence of recurrence. The patient is clinically free of disease 48 months after surgery.
Conclusion: This case represents the second documented PEComa of bladder and demonstrates
that adjuvant therapies, including anti-angiogenic and immunotherapy, may be considered for
patients with locally advanced or metastatic genitourinary PEComa.
Background
Primary perivascular epithelioid cell tumors (PEComas)
are a rare and unusual group of mesenchymal neoplasms
with unpredictable malignant potential. The term
"PEComa" was originally coined by Zamboni et al and is
the current nomenclature for tumors composed of PECs
other than angiomyolipoma (AML), clear cell sugar tumor
of lung (CCST) and lymphangioleiomyomatosis (LAM),
which are related lesions with distinct clinical features [1].
Consequent to the World Health Organization's (WHO)
endorsement of PEComa as a bonafide entity, an increas-
ing number of reports have documented PEComas arising
in varied anatomic locations, including bladder, kidney
and prostate [2-8]. Despite increasing awareness of this
entity, accurately predicting the biological behavior of
PEComas remains difficult and contemporary reports are
limited by short clinical follow-up. Herein, we report the
diagnosis, management and four-year follow-up of the
second documented case of primary PEComa of the uri-
nary bladder [8].
Case presentation
A 48-year-old man presented with dysuria, passage of uri-
nary sediment and lower abdominal discomfort. A three-
centimeter (cm) smooth, lobular mass with mild bullous
edema was identified by cystoscopy in the posterior mid-
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line of the bladder. Laboratory and staging investigations
were negative and computerized tomography (CT) sug-
gested an enterovesical fistula. The patient underwent
laparotomy, partial cystectomy and partial small bowel
resection. Pathological examination revealed PEComa of
the bladder. A search for primary melanoma was negative
and there were no stigmata of tuberous sclerosis. The
patient underwent adjuvant interferon (IFN)-α immuno-
therapy for primary PEComa of the bladder. Subsequent
follow-up evaluations were performed 3 monthly for the
first 12 months, then 6 monthly thereafter. Routine fol-
low-up procedures included clinical examination, cystos-
copy, chest roentgenography, CT of abdomen and pelvis
and routine blood work. On one occasion, positron emis-
sion tomography was performed in order to detect neo-
plastic metabolic activity. None of these follow-up
procedures revealed evidence of recurrence. The patient is
clinically free of disease 48 months after surgery.
Pathology
A fragmented specimen, 11 cm in aggregate, containing
pieces of friable, tan-colored tumor, as well as bladder and
small bowel tissue, was received for pathological exami-
nation. Histologically, the tumor was located in the blad-
der wall, but also showed infiltration into subserosal,
muscularis propria and submucosal layers of the small
bowel. The neoplastic cells were mainly epithelioid but
occasionally spindled, with abundant cytoplasm that var-
ied from eosinophilic and granular to clear (Figure 1). The
nuclei were round with little pleomorphism; they often
contained discernible nucleoli and occasional nuclear
inclusions were present. Mitoses were rare to absent and
necrosis was inconspicuous. There was no evidence of fat
or thick-walled vessels. Periodic acid-Schiff staining, with
and without diastase digestion, confirmed the presence of
abundant intracytoplasmic glycogen.
Immunohistochemically, >80% of the tumor cells dem-
onstrated strong positivity for HMB45 (cytoplasmic),
Melan-A (cytoplasmic) and smooth muscle actin (mem-
branous), while smooth muscle myosin heavy chain,
desmin and CD117 were weakly positive in <20% of the
tumor cells (Figures 2 &3). The neoplastic cells failed to
stain with antibodies against S100 protein, cytokeratin
(AE1/AE3, 8/18), vimentin, muscle specific actin,
myoglobin, CD31, CD34 and WT-1. Positive controls
were used for all markers as follows: HMB45 and Melan-
A – melanoma; S100 – schwannoma; desmin, smooth
muscle actin, muscle specific actin, smooth muscle
myosin heavy chain and myoglobin – gastrointestinal
(GI) smooth muscle; CD117 – GI mast cells and Cajal
cells; cytokeratin – GI epithelia; vimentin – GI mesen-
chyma; CD34 and CD31 – tonsillar endothelia; WT-1 –
renal glomeruli. Slides stained omitting the primary anti-
body were used as negative controls.
Discussion
The WHO has offered formal recognition to a group of
neoplasms with perivascular epithelioid cell differentia-
tion [2]. These tumors have in common the presence of
epithelioid to spindle cells with eosinophilic to clear cyto-
plasm that, with few exceptions, demonstrate positive
immunostaining for markers of both myoid (smooth
muscle actin, desmin) and melanocytic (HMB45, Melan-
A, tyrosinase) differentiation. Pathologically, the main
differential diagnoses include paraganglioma, melanoma,
clear cell sarcoma of soft parts (CCSSP), metastatic carci-
noma (especially from kidney or adrenal gland) and epi-
thelioid sarcoma.
While distinct clinicopathological entities included
within the PEComa group include AML, LAM and CCST,
other PEC-derived tumors have been documented at an
increasing number of anatomical sites, including pan-
creas, small and large intestine, ligamentum teres/falci-
form ligament, common bile duct, bladder, prostate,
breast, uterus, cervix, vulva, ovary, broad ligament, heart,
base of skull, and soft tissue [3-8]. The term "PEComa"
has become the popular umbrella term for this latter list
of lesions. Only one case of primary bladder PEComa has
been described previous to ours. Pan et al reported a case
of PEComa occurring in the deep detrusor muscle of the
bladder in a 33-year-old woman, which was an incidental
discovery during work-up for dysmenorrhea [8]. While
there were no worrisome clinicopathological features of
the tumor and the patient remained tumor free during the
Tumor cells were mainly epithelioid with abundant eosi- nophilic and granular cytoplasm Figure 1
Tumor cells were mainly epithelioid with abundant eosi-
nophilic and granular cytoplasm. Occasional nuclear inclu-
sions were present (hematoxylin-eosin, original magnification 
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entire six-year follow-up period, there was no description
of post-operative treatment.
PEComas demonstrate uncertain tumor biology and
unpredictable clinical behavior. While the majority of
reported "PEComas" have behaved in a benign fashion,
an important minority have demonstrated malignant
behavior with locally destructive recurrences, distant
metastases and patient death, underscoring the need for
accurate identification and effective treatment strategies
[4,5,7]. When Folpe et al combined results of 24 of their
own cases of PEComa of soft tissue and gynecological ori-
gin with data from 45 previously reported cases of
PEComa, they found that recurrence and metastasis were
associated with tumor size >5 cm, infiltrative growth pat-
tern, high nuclear grade, necrosis and a mitotic index of
>1 per 50 high power fields [9,10]. However, other
authors feel that accurate criteria which reliably predict
the behavior of PEComas remain lacking [10]. In the
present case, the surgical margins were not evaluable, due
to the fragmented nature of the specimen, and lymph
nodes were not sampled, since the intraoperative impres-
sion was that of a benign enterovesical fistula, rather than
a potentially malignant neoplasm.
Optimal treatment for PEComas is not known at this
time. Primary excision is usually curative, as most tumors
are benign. However, locally advanced or metastatic dis-
ease portends a poor prognosis and strategies incorporat-
ing chemotherapy, radiation and immunotherapy have
been reported. In this patient, a one-year course of adju-
vant IFN-α 2b at 10 million units given subcutaneously
three times per week was initiated based on the vascular
nature of this tumor and IFN-α's additional anti-ang-
iogenic effect [11]. While IFN-α 2b therapy for the man-
agement of PEComa remains experimental, other authors
have described the efficacy of IFN-α 2a in causing regres-
sion of life-threating hemangiomas in infants [12,13].
While fever, neutropenia and skin necrosis have been
reported as uncommon, short-term side effects of IFN-α
2a, no such effects were seen in the present case [12]. As
there was no evidence of residual tumor in the present
case, a limitation of our report would be that the effect of
IFN-α on PEComa morphology could not be docu-
mented. Thus, further studies are needed to clarify the
clinical and pathological effects of IFN-α therapy in
patients with PEComa and the risks of IFN therapy should
be weighed against the potential benefits in any patient
lacking detectable residual tumor. Partial, complete and
absent responses have also been noted for dacarbazine,
vincristine and imatinib mesylate, a tyrosine-kinase
inhibitor [14]. Adjuvant radiation for CCSSP has also
been reported following wide surgical excision, with pri-
mary site irradiation appearing to confer a survival benefit
for disease located in soft tissue of the extremities [15].
Conclusion
In summary, we report the first case of PEComa of the
bladder treated with adjuvant IFN-α immunotherapy,
with long-term follow-up. Given the uncertainty of
PEComa tumor biology, adjuvant therapies, including
anti-angiogenic and immunotherapy, may be considered
for patients with locally advanced or metastatic genitouri-
nary PEComa.
Tumor cells showed strong and diffuse membranous positiv- ity for smooth muscle actin (smooth muscle actin immu- noperoxidase, original magnification ×400) Figure 3
Tumor cells showed strong and diffuse membranous positiv-
ity for smooth muscle actin (smooth muscle actin immu-
noperoxidase, original magnification ×400).
Tumor cells demonstrated strong and diffuse cytoplasmic  positivity for HMB45 and Melan-A (Melan-A immunoperoxi- dase, original magnification ×400) Figure 2
Tumor cells demonstrated strong and diffuse cytoplasmic 
positivity for HMB45 and Melan-A (Melan-A immunoperoxi-
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